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1024-50 Recanalized Chronic Total Occlusions Covered by 
Sirolimus-Eluting Stents
José Suárez de Lezo, José Segura, Alfonso Medina, Manuel Pan, Antonio Delgado, 
Miguel Romero, Juan Herrador, Isabel Ureña, Djordje Pavlovic, Federico Segura, 
Francisco Melián, Luis Burgos, Reina Sofía Hospital, Córdoba, Spain, Dr. Negrín 
Hospital, Las Palmas de Gran Canaria, Spain
Background: Chronic total coronary occlusions leading to residual myocardial ischemia
may be recanalized and scaffolded by stents. The initial and long-term efficacy of this
treatment with bare stents is well known. A high restenosis rate (20-30%) remains the
main limitation. At present, there is little information on the use of Rapamycin-eluted
stents (RES) to treat chronic total occlusions. Methods: Since May/02 we have prospec-
tively analyzed the initial and late findings observed in a consecutive series of 86 patients
(pts) with angina pectoris due to chronic total coronary occlusion in whom we attempted
recanalization and subsequent covering by RES. The mean age was 60±10 years; 65
(76%) were male. The underlying clinical condition was stable angina in 15 pts and
unstable angina in 71 pts; 34 had had a previous myocardial infarction. The estimated
occlusion time in 49 pts was 9±21 months; however, the overall duration of symptoms
was 2.5±3 years. At cardiac catheterization, left ventricular end-diastolic pressure was
21±8 mmHg and the ejection fraction 58±13%. One patient had 2 occluded arteries.
Recanalization was attempted with the safer-cross radiofrequency wire in 20 pts because
of unfavourable anatomy or too old occlusion; in the remaining 66, recanalization was
attempted with regular guide-wires. Once recanalization had been achieved (86%) bal-
loon dilatation and subsequent scaffolding with RES was performed. Results: Primary
success was obtained in 74 pts. In the remaining 12 pts (14%) we failed to cross the
occlusion. Two pts (2.3%) had a cardiac tamponade that was resolved by percutaneous
drainage in the laboratory. All recanalized pts became symptoms free. After a mean clini-
cal follow-up time of 6±3 months, 5 pts (6%) needed new target lesion revascularization.
Thirty-nine pts underwent 6-month follow-up angiographic and intracoronary ultrasound
(IVUS) re-evaluation. The mean neointimal area, as derived by IVUS, was 1.1±1.8 mm².
Restenosis rate was 13%. Conclusion: The use of drug-eluting stents to cover recana-
lized chronic total occlusions is safe and seems to significantly reduce the need for fur-
ther target vessel revascularization.
1024-51 Evaluation of Sirolimus-Eluting Stents for the Treatment 
of Bifurcation Lesions: A Real World Study
Gunasekaran Sengottuvel, Thierry Lefèvre, Yves Louvard, Pierre Dumas, Mehran 
Monchi, Marie-Claude Morice, Institut Cardiovasculaire Paris Sud, Massy, France
Background: Although bare metal stents have been a useful therapeutic modality for the
treatment of bifurcation lesions using a “provisional T stenting strategy”, they have not
eliminated the problem of restenosis. Sirolimus-eluting stents have been shown to mark-
edly decrease restenosis in selected lesions.
Methods : We evaluated from our prospective database on bifurcation lesions the out-
come of patients who underwent treatment with sirolimus-eluting stents.
Results: Between May 2002 and July 2003, a total of 140 patients underwent coronary
stenting for the treatment of bifurcation lesions and of these 48 patients (49 lesions) were
treated with a Cypher stent. They were 64+8 years, 73% male, 48% diabetes mellitus,
and 30% had unstable angina. Lesions were true bifurcation lesions in 49% of cases.
Bifurcations involved mainly LAD/ Diag (63%). The reference diameter of the main and
side branch was 3.0+0.4 mm and 2.0+0.2 mm respectively. Provisional T-stenting of the
side branch was used in 86% of cases (side branch was stented in 11% of cases) , sys-
tematic T stenting in 9% and V stenting in 5 % of cases. In the provisional T-stenting
group, all patients had final kissing balloon inflation after opening the stent strut. Device
success was obtained in all cases. Angiographic success was 100% and 97.6% for the
main and the side branch respectively. In-hospital period was uneventful except for
asymptomatic CPK elevation in one patient. Of the 28 patients who completed 6 month
follow-up, there were no case of stent thrombosis, death or MI. Two patients had angio-
graphic restenosis, first was focal in-stent restenosis of the main branch and the second,
ostial restenosis of the unstented side branch.
Conclusion: Implantation of the sirolimus-eluting stent at coronary bifurcations mainly
using a strategy of provisional T stenting results in low clinical event rates. These prelimi-
nary results appear very promising. Six-month results of the total cohort will be pre-
sented at the meeting.
1024-52 The Crushing Technique for Bifurcation Lesions: 
Immediate and Mid-Term Clinical Outcome
Flavio Airoldi, Goran Stankovic, Dejan Orlic, Alaide Chieffo, Carlo Briguori, Mauro 
Carlino, Matteo Montorfano, Ghada Mikhail, Iassen Michev, Giancarlo Vitrella, Carlo Di 
Mario, Antonio Colombo, EMO Centro Cuore Columbus, Milan, Italy, San Raffaele 
Hospital, Milan, Italy
Background: different modalities of stenting have been proposed for bifurcational
lesions requiring one or two stents positioned with different techniques.
Methods: we report the immediate and 6-months clinical outcome of a new stenting
technique employed in the first 91 consecutive bifurcational lesions from 86 patients
using drug eluting stents (Sirolimus, n=73, Taxol, n=13). This new mode of bifurcational
stenting, reproduces the same steps of the modified T-stenting with the only difference
being the protrusion of the side branch stent into the main vessels for 4-5 mm from the
carina. The aim of this technique is to ensure that the ostium of the side branch is circum-
ferentially covered with stent struts with the additional advantage of a higher dosage of
eluted drug near the bifurcational site.
Results: angiographic success was reached in all the lesions (final kissing balloon infla-
tion in 63% of the lesions). Bifurcational lesions were located as follows: LAD-diagonal
branch 48%, LCX-OM 27%, RCA 11%, LM 11%. Procedural success was obtained in 82
(95.3%) patients. During hospital stay, no patient died; 3 (4.7%) patients had myocardial
infarction. All the patients have been discharged with double antiplatelet therapy for at
least 6 months. No other major adverse cardiac events were observed during the first
month of follow-up. After 6-months clinical follow-up no patients died, 2 (2.3%) patients
had myocardial infarction. Target lesion revascularizations (TVR) were performed in 8/42
(19%) patients (on the main branch in 1 case, on the side branch in 7 cases). A lower,
even though not statistically different, incidence of TVR was observed in the lesions
where a final kissing balloon inflation was performed (8% with kissing vs 20% without
kissing, p=0.45).
Conclusions: treatment of bifurcation lesions using the “crushing” stent technique is fea-
sible with acceptable rate of procedural complications. Need of repeat revascularization
have been found to be low on the main branch, but relatively high on the side branch.
Final kissing balloon inflation can be a potential mean to improve the mid term outcome
but need to be confirmed in further evaluations.
1024-53 Drug-Eluting Stents for Coronary Bifurcations: Bench-
Top Insights Into the "Crush" Technique
John A. Ormiston, Erin Currie, Mark WI Webster, Patrick Kay, Peter N. Ruygrok, James T. 
Stewart, Monique J. Panther, Mercy Angiography, Auckland, New Zealand
Background: Compared with bare metal stents, sirolimus-eluting stents appear to
reduce restenosis after bifurcation stenting. The "crush" technique is proposed to further
reduce restenosis by improving stent and drug application to the side-branch ostium.
Aims: To investigate the "crush" technique for different drug-eluting platforms, to identify
pitfalls and clarify the best implantation strategies.
Methods and Results: Each stage of the "crush" technique was photographed in a bifur-
cation phantom for 3 stent designs (BxVelocity, Express II, and Driver). Simultaneous
side-branch and main vessel post-dilatation ("kissing" balloons) with appropriately sized
balloons, fully expanded the stent in the side-branch ostium (A to B in figure), widened
the gaps between stent struts covering the side-branch, and prevented or corrected main
vessel stent distortion which occurred if the main vessel was post-dilated with an under-
sized main vessel balloon (C).
Conclusions: Appropriate side-branch and main vessel post-dilatation is needed to
expand the stent at the ostium fully, to widen gaps between stent struts overlying the
side-branch (facilitating subsequent access), and to prevent stent distortion. These prin-
icples applied to all bifurcation stent strategies and stent designs tested.
1024-54 Low Repeat Revascularization Rates Following Drug-
Eluting Stent Implantation in De Novo Bifurcation 
Lesions
Angela Hoye, Pedro A. Lemos, Kengo Tanabe, Chourmouzios Arampatzis, Francesco 
Saia, Jiro Aoki, Muzaffer Degertekin, Andrew T L Ong, Carlos van Mieghem, Sjoerd H. 
Hofma, Georgios Sianos, Pieter C. Smits, Willem van der Giessen, Eugene McFadden, 
Pim de Feyter, Patrick W. Serruys, Thoraxcenter, Rotterdam, The Netherlands
Background: Bifurcation lesions demonstrate high restenosis when treated with conven-
tional stents. We evaluated both the sirolimus-eluting (SES) and paclitaxel-eluting stent
(PES) in this high risk population.
Methods: Since April 2002, the default strategy at our institution was to use drug-eluting
stents in all patients. In the 2nd quarter of 2003, we switched from SES to PES for all pro-
cedures. The current study evaluated 199 consecutive patients treated for de novo bifur-
cation stenoses with either SES (n=127) or PES (n=72) implantation into both main
vessel and side branch. All were followed-up for clinical events, with additional angiogra-
phy in those enroled in the first 6months.
Results: Presentation: stable angina 60%, acute myocardial infarction 12%. There were
5 subacute thromboses (2.5%), 4 in patients initially treated for AMI. A total of 228
lesions were treated. Target lesion revascularization rate was 7%, and target vessel
revascularization (TVR) 9%. Follow-up angiography (in 70% of those eligible), revealed
binary restenosis of 9% in the main vessel and 14% in the side branch. 5 of the 6 side
branch restenoses were ostial and followed T-stenting. The stenting technique used is
depicted in the figure. Further follow-up data of both periods will be available at the ACC.
Conclusions: Both SES and PESs used for bifurcation lesions, demonstrate a low rate
of TVR. Ensuring complete lesion coverage with drug-eluting stents may further reduce
restenosis particularly at the ostium of the side branch. 
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1025-41 Insulin Sensitizers Are Associated With Improved 
Outcomes in Diabetic Patients Undergoing 
Brachytherapy
John A. Kao, Mark Grise, Peter Castarella, Huan Giap, Aniradha Koka, Gerard Huppe, 
Kathleen Sirkin, Prabhakar Tripuraneni, Paul S. Teirstein, Scripps Clinic, La Jolla, CA
BACKGROUND: Diabetics have worse baseline disease and higher restenosis rates
than non-diabetics. Insulin sensitizers may decrease cardiovascular events in diabetics.
Our goal was to determine the effect of insulin sensitizers on clinical events of diabetics
undergoing brachytherapy for in-stent restenosis.
METHODS: Diabetics receiving brachytherapy in SCRIPPS I, II, III, and IV at Scripps
Clinic were divided into two groups; insulin sensitizers (biguanides or thiazolidinediones,
n=50), and non-sensitizers (insulin, sulfonylureas or diet, n=67). Clinical events were
defined as target vessel revascularization (TVR), MI (STEMI and NSTEMI), non-TVR,
and death.
RESULTS: By 12 months a significant reduction in the composite endpoint was observed
in the insulin sensitizer group with a significant decrease in the individual endpoint of
Death. Treatment with an insulin sensitizer was the strongest predictor of clinical events
(OR=3.47, p=0.0035). This effect was independent of adjunctive medical therapy for cor-
onary artery disease. Patients treated with insulin alone had equivalent outcomes com-
pared to patients treated with sulfonylureas or sulfonylureas with insulin (p>0.05 for all
comparisons).
CONCLUSIONS: Insulin sensitizers improve clinical outcomes and convey a mortality
benefit in diabetics undergoing brachytherapy for in-stent restenosis. The increased
events in the non-sensitizer group is not driven by by patients receiving insulin therapy. 
1025-42 Abciximab Administration for the Prevention of 
Angiographic Restenosis in Small Coronary Arteries: 
Results From the Randomized ISAR-SMART-2 Trial
Jörg Hausleiter, Adnan Kastrati, Julinda Mehilli, Helmut Schühlen, Sonja Siebert, Franz 
Dotzer, Josef Dirschinger, Albert Schömig, Deutsches Herzzentrum München, Munich, 
Germany, 1.Medizinische Klinik, Klinikum rechts der Isar, Munich, Germany
On the basis of non-dedicated studies it is believed that abciximab reduces the risk of
restenosis after percutaneous coronary interventions. In the current multi-center trial,
patients with symptomatic coronary artery disease and lesions in small coronary arteries
(vessel size < 2.8mm) were randomized to receive stenting (phosphorylcholine-coated
stent) or PTCA as well as abciximab or placebo by a 2x2 factorial design. The objective
of the pharmacological aspect of the ISAR-SMART-2 trial was to assess whether abcix-
imab administration is associated with a reduction in angiographic restenosis in small
coronary arteries.
Methods: From July 2000 through May 2002, a total of 502 patients were randomly
assigned to abciximab administration (251 pts) or placebo (251 pts). The primary end-
point of the study was the incidence of angiographic restenosis (>= 50% diameter steno-
sis) at repeat angiography (available in 82% of patients). All patients received a loading
dose of 600mg clopidogrel at least 2 hours before the intervention.
Results: The incidence of major adverse cardiac events did not differ at 30 days after
intervention. The restenosis rate and the rate of target vessel revascularization at 1 year
are shown in the Figure.
Conclusion: These results show that abciximab administration on top of an high-dose clo-
pidogrel loading does not provide protection against restenosis after percutaneous coro-
nary interventions in small coronary arteries. 
1025-43 Bivalirudin Confers Antiplatelet Effects in Patients 
Undergoing Percutaneous Coronary Intervention
Sunil X. Anand, Michael C. Kim, Mazullah Kamran, Samin K. Sharma, Frank Carbon, 
Erdal Cavusoglu, Juan F. Viles-Gonzalez, Juan J. Badimon, Jonathan D. Marmur, The 
Zena and Michael A. Weiner Cardiovascular Institute, Mount Sinai School of Medicine, 
New York, NY, SUNY Health Science Center at Brooklyn, Brooklyn, NY
Background: Thrombin activity is paramount in the formation of platelet-mediated acute
thrombosis precipitated by atherosclerotic plaque rupture or endothelium disruption
resulting from mechanical intervention. The objective of this study was to investigate and
compare the effects of a bivalent direct thrombin inhibitor, bivalirudin, with unfractionated
heparin (UFH) on platelet function in the setting of percutaneous coronary intervention
(PCI).
Methods: Patients (mean age 61.7 ± 11.1) were administered an intravenous 0.75 mg/
kg bolus followed by a 1.75 mg/kg/hr infusion of bivalirudin (n=12) or an intravenous 40-
50 U/kg bolus of UFH (n=15) during PCI. No patient received a pre-loading dose of clopi-
dogrel. Blood samples were collected from patients at baseline and 5 minutes after drug
administration from the femoral artery access sheath. To determine platelet function (by
assessing platelet surface coverage), the cone and platelet analyzer assay was per-
formed on all samples at a high shear rate (1875 s-1). Computerized planimetry mea-
surements were performed, and 4 to 16 images per timepoint were quantified for platelet
surface coverage (PSC) in a blinded fashion.
Results: Direct thrombin inhibition by bivalirudin resulted in a marked 34 ± 6 % reduction
in PSC as compared to baseline values (*p < 0.001). On the other hand, UFH demon-
strated a remarkable 29 ± 8% increase in PSC as compared to baseline values (*p <
0.05). No clinical sequalae were experienced by any patient.
Conclusion: Our data suggests that direct thrombin inhibition by bivalirudin administra-
tion during PCI confers a profound anti-platelet effect as compared to UFH. Interestingly,
UFH administration leads to significant platelet activation and aggregation during PCI.
Sensitizers
N=50
Non-Sensitizer 
Therapy
N=67
P Value
6-Month Combined Event Rate (%) 27.3% 31.9% 0.72
Death 0 7% 0.13
MI 6% 9% 0.81
TVR 18% 18% 0.33
Non-TVR 15% 10% 0.33
12 Month Combined Event Rate (%) 37% 57.4% 0.041
Death 0 10% 0.049
MI 6% 12% 0.44
TVR 30% 30% 0.61
Non-TVR 10% 15% 0.61
